The director of UNMC’s Adult Cystic Fibrosis program says he’s excited about a new treatment called Kalydeco.
Dr. Peter J. Murphy says Kalydeco is a drug that specifically targets a certain class of genetic mutation that causes cystic fibrosis in some patients. Cystic fibrosis is a disease that primarily affects the lungs, with thick secretions that may sometimes become infected and make it difficult for patients to breathe.
